Medirom Healthcare Technologies Inc.: Form 20-F for the period ended Dec 31, 2023
Filed with the SEC on Jun 18, 2024 and accepted by EDGAR at Jun 18, 2024, 21:29 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-01-01 to 2023-12-31 | JPY 6.83bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Selling, general and administrative | 12 months2023-01-01 to 2023-12-31 | JPY 1.96bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2023-01-01 to 2023-12-31 | −JPY 391.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2023-01-01 to 2023-12-31 | JPY 36.9m | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-01 to 2023-12-31 | −JPY 94.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-01 to 2023-12-31 | JPY 115.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | JPY 22.34 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | JPY 23.64 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 5,166,653 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −JPY 631.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | JPY 135.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-12-31 | $755.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | JPY 1.76bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | JPY 6.85bn | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | JPY 3.56bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | JPY 6.63bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-12-31 | JPY 1.05bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-12-31 | JPY 100.4m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2023-12-31 | JPY 400.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2023-12-31 | JPY 210.9m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2023-12-31 | 4,882,500 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001558370-24-009293. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.